SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VISX
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: pappy who wrote (522)4/18/1998 1:28:00 AM
From: yosid  Read Replies (1) of 1754
 
Pappy ( That LCAV stock dividend must look real good now! )
If Summit can buy better technology via acquisition, I would think that would be enough to secure their installed base position. They would simply petition to replace their old machines with new, state of the art, lasers.
What happens if the FED kills PPP?
I can see BEAM and VISX being able to function using each other's patent rights without penalty, but how would a competing manufacturer be charged a royalty. I thought the technology was based on joint patents being used indivisible of each other. If this is true, I would think the fee charged by either Beam or Visx would be at their discretion. No matter what the patent participation, a new machine could not be produced without permission from both companies.
Would this allow Summit to charge as much as Visx as a royalty?
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News